Role of a second chemotherapy in recurrent malignant glioma patients who progress on bevacizumab

Bevacizumab is a humanized monoclonal antibody against vascular endothelial growth factor (VEGF) that has efficacy in recurrent malignant gliomas, particularly in combination with irinotecan. However, responses are rarely durable. Continuation of bevacizumab in combination with another chemotherapeu...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Quant, Eudocia C., Norden, Andrew D., Drappatz, Jan, Muzikansky, Alona, Doherty, Lisa, LaFrankie, Debra, Ciampa, Abigail, Kesari, Santosh, Wen, Patrick Y.
Médium: Artigo
Jazyk:Inglês
Vydáno: Duke University Press 2009
Témata:
Clinical Investigations
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC2765344/
https://ncbi.nlm.nih.gov/pubmed/19332770
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1215/15228517-2009-006
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky